[Postmenopausal hemorrhage and endometrial cancer in tamoxifen therapy].

A. Krause, Krause A, B. Gerber, Gerber B
Zentralblatt für Gynäkologie · 1994 · vol. 116(1) , pp. 44–7 · PMID:8147180 · W2416876699
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This report describes 8 patients experiencing endometrial pathology during tamoxifen therapy, including one endometrial cancer, leading to discussions on tamoxifen's endometrial effects, prevention, and screening recommendations.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Report about 8 patients with endometrial pathology during tamoxifen therapy: 1 endometrial cancer, 1 adenomyosis uteri and 6 endometrial polyps. The knowledge about effects of tamoxifen on endometrium and possibilities of prevention are discussed. Sonographic screening of patients during tamoxifen therapy and if need by endometrial biopsy is necessary especially if tamoxifen is given longer than 2 years. No more than 30 mg should given in adjuvant therapy.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Breast Neoplasms Endometrial Neoplasms Tamoxifen Uterine Hemorrhage Aged Breast Neoplasms Breast Neoplasms Combined Modality Therapy Endometrial Neoplasms Endometrial Neoplasms Endometrium Endometrium Female Humans Middle Aged Neoplasm Staging Polyps Polyps Polyps Tamoxifen

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

europepmc
last seen: 2026-09-05T06:14:40.014199+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:11:29.222973+00:00
License: CC0 · commercial use OK